A carregar...
The role of dasatinib in the management of chronic myeloid leukemia
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) for chronic, blastic, or accelerated phase chronic myeloid leukemia (CML) patients who are resistant or intolerant to previous treatment. It potently inhibits BCR/ABL and SRC-family kinases (SRC, LCK, HCK, YES, FYN, FGR, BLK, LYN, FRK)...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4330036/ https://ncbi.nlm.nih.gov/pubmed/25709401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S80207 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|